Drug Profile
Research programme: co-morbid hypertension and type 2 diabetes therapy - MicroDose Therapeutx
Alternative Names: MetPrilLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MicroDose Therapeutx
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in USA (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO, Capsule)
- 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries